An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

Summary

An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.

Timeline

Start

2023-05-30

Primary completion

2024-10-02

Completion

2024-10-02

Drugs

Indications